Trade Repligen - RGEN CFD

Add to favourite

156.92

2.36%

View detailed chart

To be able to trade stocks like this, create an account and apply for a stock listing.

Create Account

Summary
Historical Data
Events
Income Statement
Balance Sheet
Cash Flow

Trading сonditions

Spread

0.30

Long position overnight fee

-0.026179%

Short position overnight fee

0.003957%

Overnight fee time

21:00 (UTC)

Min traded quantity

Currency

USD

Margin

Stock exchange

United States of America

Commission on trade

*Information provided by Capital.com

Repligen Corp ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats

Prev. Close*	160.81
Open*	153.65
1-Year Change*	-11.15%
Day's Range*	153.65 - 158.58
52 wk Range	110.45-200.98
Average Volume (10 days)	503.83K
Average Volume (3 months)	13.29M
Market Cap	9.73B
P/E Ratio	85.73
Shares Outstanding	55.83M
Revenue	669.78M
EPS	2.03
Dividend (Yield %)	N/A
Beta	1.04
Next Earnings Date	Feb 20, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Apr 18, 2024	157.01	3.11	2.02%	153.90	158.76	152.03
Apr 17, 2024	160.81	-2.73	-1.67%	163.54	165.13	160.15
Apr 16, 2024	164.07	-0.88	-0.53%	164.95	165.17	160.78
Apr 15, 2024	166.28	-4.93	-2.88%	171.21	172.60	165.65
Apr 12, 2024	171.43	-2.41	-1.39%	173.84	174.30	169.66
Apr 11, 2024	175.97	1.08	0.62%	174.89	176.64	174.29
Apr 10, 2024	175.89	1.96	1.13%	173.93	177.59	173.89
Apr 9, 2024	181.83	7.87	4.52%	173.96	181.91	171.89
Apr 8, 2024	173.94	0.78	0.45%	173.16	175.52	171.89
Apr 5, 2024	173.52	0.63	0.36%	172.89	177.31	172.44
Apr 4, 2024	172.68	-5.22	-2.93%	177.90	179.77	172.65
Apr 3, 2024	177.11	1.63	0.93%	175.48	179.31	175.48
Apr 2, 2024	177.68	-0.13	-0.07%	177.81	179.10	176.29
Apr 1, 2024	182.84	-0.99	-0.54%	183.83	183.83	179.98
Mar 28, 2024	183.74	1.02	0.56%	182.72	187.09	181.89
Mar 27, 2024	184.58	-0.32	-0.17%	184.90	185.39	183.23
Mar 26, 2024	183.66	-0.23	-0.13%	183.89	186.46	183.23
Mar 25, 2024	184.74	-12.24	-6.21%	196.98	197.57	184.14
Mar 22, 2024	197.72	-1.76	-0.88%	199.48	199.92	196.65
Mar 21, 2024	199.43	3.07	1.56%	196.36	199.97	196.36

Repligen Events

Time (UTC)	Country	Event
Tuesday, April 30, 2024
Time (UTC) 12:30	Country US	Event Q1 2024 Repligen Corp Earnings Release Q1 2024 Repligen Corp Earnings Release Forecast - Previous -
Thursday, May 16, 2024
Time (UTC) 12:00	Country US	Event Repligen Corp Annual Shareholders Meeting Repligen Corp Annual Shareholders Meeting Forecast - Previous -
Friday, May 17, 2024
Time (UTC) 12:00	Country US	Event Repligen Corp Annual Shareholders Meeting Repligen Corp Annual Shareholders Meeting Forecast - Previous -
Wednesday, July 31, 2024
Time (UTC) 12:30	Country US	Event Q2 2024 Repligen Corp Earnings Release Q2 2024 Repligen Corp Earnings Release Forecast - Previous -

View all events

Annual
Quarterly

	2022	2021	2020	2019	2018
Total revenue	801.536	670.534	366.26	270.245	194.032
Revenue	801.536	670.534	366.26	270.245	194.032
Cost of Revenue, Total	345.83	279.28	156.634	119.099	86.531
Gross Profit	455.706	391.254	209.626	151.146	107.501
Total Operating Expense	576.866	503.298	296.437	239.812	168.044
Selling/General/Admin. Expenses, Total	188.813	157.225	99.589	82.013	52.192
Research & Development	43.936	34.274	20.182	19.45	15.821
Unusual Expense (Income)	-28.729	10.578	4	5.65	2.9
Operating Income	224.67	167.236	69.823	30.433	25.988
Interest Income (Expense), Net Non-Operating	5.816	-12.538	-10.392	-3.968	-4.814
Other, Net	-11.346	-1.155	-0.214	-0.314	0.262
Net Income Before Taxes	219.14	153.543	59.217	26.151	21.436
Net Income After Taxes	185.959	128.291	59.926	21.411	16.617
Net Income Before Extra. Items	185.959	128.291	59.926	21.411	16.617
Net Income	185.959	128.291	59.926	21.411	16.617
Income Available to Common Excl. Extra. Items	185.959	128.291	59.926	21.411	16.617
Income Available to Common Incl. Extra. Items	185.959	128.291	59.926	21.411	16.617
Diluted Net Income	186.346	128.291	59.926	21.411	16.617
Diluted Weighted Average Shares	57.455	57.264	53.892	49.206	45.471
Diluted EPS Excluding Extraordinary Items	3.24334	2.24034	1.11196	0.43513	0.36544
Diluted Normalized EPS	3.03077	2.55806	1.58048	0.77026	0.41488
Total Extraordinary Items
Depreciation / Amortization	27.016	21.941	16.032	13.6	10.6
Dilution Adjustment	0.387

	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022
Total revenue	159.169	182.66	186.762	200.741	207.633
Revenue	159.169	182.66	186.762	200.741	207.633
Cost of Revenue, Total	79.307	81.845	90.7	86.514	86.26
Gross Profit	79.862	100.815	96.062	114.227	121.373
Total Operating Expense	139.77	151.404	137.925	148.076	144.465
Selling/General/Admin. Expenses, Total	48.966	56.17	53.237	53.643	54.649
Research & Development	9.706	12.154	11.113	10.228	10.44
Unusual Expense (Income)	1.791	1.235	-17.125	-2.309	-6.884
Operating Income	19.399	31.256	48.837	52.665	63.168
Interest Income (Expense), Net Non-Operating	5.69	5.216	3.746	1.848	0.437
Other, Net	0.071	-0.38	0.403	-7.046	-3.849
Net Income Before Taxes	25.16	36.092	52.986	47.467	59.756
Net Income After Taxes	20.064	28.829	48.729	40.405	49.861
Net Income Before Extra. Items	20.064	28.829	48.729	40.405	49.861
Net Income	20.064	28.829	48.729	40.405	49.861
Income Available to Common Excl. Extra. Items	20.064	28.829	48.729	40.405	49.861
Income Available to Common Incl. Extra. Items	20.064	28.829	48.729	40.405	49.861
Diluted Net Income	20.064	28.829	48.729	40.405	49.861
Diluted Weighted Average Shares	56.858	57.049	57.026	57.304	56.721
Diluted EPS Excluding Extraordinary Items	0.35288	0.50534	0.8545	0.7051	0.87906
Dividends per Share - Common Stock Primary Issue	0	0		0	0
Diluted Normalized EPS	0.40401	0.59044	0.63334	0.7303	0.82855
Dilution Adjustment			0	0	0

Annual
Quarterly

	2022	2021	2020	2019	2018
Total Current Assets	998.118	931.677	902.382	641.828	275.739
Cash and Short Term Investments	623.757	603.814	717.292	528.392	193.822
Cash & Equivalents	523.458	603.814	717.292	528.392	193.822
Short Term Investments	100.299
Total Receivables, Net	116.766	121.39	74.038	46.391	36.596
Accounts Receivable - Trade, Net	116.247	117.42	71.257	43.068	33.015
Total Inventory	238.277	184.494	95.025	54.832	42.263
Prepaid Expenses	1.909	2.713	1.936	0.08	0.629
Other Current Assets, Total	17.409	19.266	14.091	12.133	2.429
Total Assets	2524.66	2358.35	1902.89	1400.11	774.621
Property/Plant/Equipment, Total - Net	315.696	226.523	92.046	74.162	32.18
Property/Plant/Equipment, Total - Gross	408.003	297.24	141.102	109.541	60.492
Accumulated Depreciation, Total	-92.307	-70.717	-49.056	-35.379	-28.312
Goodwill, Net	855.513	860.362	618.305	468.413	326.735
Intangibles, Net	353.676	337.274	287.1	212.552	135.438
Long Term Investments
Other Long Term Assets, Total	1.655	2.518	3.054	3.158	4.529
Total Current Liabilities	404.196	375.262	318.956	48.313	129.842
Accounts Payable	27.554	36.203	16.88	11.425	10.489
Accrued Expenses	56.335	63.969	41.598	28.009	13.551
Notes Payable/Short Term Debt	0	0	0	0	0
Other Current Liabilities, Total	35.692	19.832	16.741	8.879	2.314
Total Liabilities	613.958	608.287	373.737	340.345	159.053
Total Long Term Debt	0	0	0	232.767	0
Long Term Debt			0	232.767	0
Other Liabilities, Total	186.762	199.545	27.749	29.321	4.125
Total Equity	1910.7	1750.07	1529.15	1059.77	615.568
Common Stock	0.556	0.553	0.548	0.521	0.439
Additional Paid-In Capital	1547.27	1572.34	1460.75	1068.43	642.59
Retained Earnings (Accumulated Deficit)	397.272	194.06	65.769	5.843	-15.568
Unrealized Gain (Loss)
Other Equity, Total	-34.394	-16.886	2.085	-15.027	-11.893
Total Liabilities & Shareholders’ Equity	2524.66	2358.35	1902.89	1400.11	774.621
Total Common Shares Outstanding	55.5577	55.3215	54.7608	52.0783	43.9174
Deferred Income Tax	23	33.48	27.032	29.944	25.086
Current Port. of LT Debt/Capital Leases	284.615	255.258	243.737	0	103.488

	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022
Total Current Assets	978.456	998.583	1018.8	998.118	953.233
Cash and Short Term Investments	630.779	603.656	618.018	623.757	573.363
Cash & Equivalents	630.779	603.656	516.609	523.458	573.363
Total Receivables, Net	106.158	120.304	133.488	116.247	117.645
Accounts Receivable - Trade, Net	106.158	120.304	133.488	116.247	117.645
Total Inventory	211.372	240.869	244.704	238.277	242.695
Prepaid Expenses	30.147	33.754	22.593	19.837	19.53
Total Assets	2514.13	2549	2538.23	2524.66	2462.53
Property/Plant/Equipment, Total - Net	319.702	324.608	314.502	315.696	295.777
Property/Plant/Equipment, Total - Gross	439.455	433.516	414.878	408.003	379.881
Accumulated Depreciation, Total	-119.753	-108.908	-100.376	-92.307	-84.104
Goodwill, Net	869.252	870.688	856.301	855.513	851.406
Intangibles, Net	343.729	351.704	346.595	353.676	359.56
Other Long Term Assets, Total	2.99	3.42	2.033	1.655	2.556
Total Current Liabilities	363.364	373.583	405.321	404.196	410.696
Accounts Payable	18.961	23.787	26.401	27.554	25.251
Accrued Expenses	32.533	29.225	44.889	56.335	64.755
Notes Payable/Short Term Debt	0	0	0	0	0
Current Port. of LT Debt/Capital Leases	285.956	285.521	285.072	284.615	284.165
Other Current Liabilities, Total	25.914	35.05	48.959	35.692	36.525
Total Liabilities	525.572	578.077	597.742	613.958	627.423
Total Long Term Debt	0	0	0	0	0
Deferred Income Tax	14.036	21.897	22.05	23	23.413
Other Liabilities, Total	148.172	182.597	170.371	186.762	193.314
Total Equity	1988.56	1970.93	1940.49	1910.7	1835.11
Common Stock	0.558	0.557	0.556	0.556	0.555
Additional Paid-In Capital	1567.23	1561.39	1544.96	1547.27	1541.27
Retained Earnings (Accumulated Deficit)	464.337	446.165	426.101	397.272	348.543
Other Equity, Total	-43.571	-37.189	-31.121	-34.394	-55.261
Total Liabilities & Shareholders’ Equity	2514.13	2549	2538.23	2524.66	2462.53
Total Common Shares Outstanding	55.7747	55.7449	55.6443	55.5577	55.5196
Other Current Assets, Total
Short Term Investments	0	0	101.409	100.299
Redeemable Preferred Stock	0	0

Annual
Quarterly

	2022	2021	2020	2019	2018
Net income/Starting Line	185.959	128.291	59.926	21.411	16.617
Cash From Operating Activities	172.083	119.016	62.625	67.216	32.77
Cash From Operating Activities	50.985	38.447	27.067	20.868	15.778
Deferred Taxes	-1.352	6.517	-3.992	-0.624	0.071
Non-Cash Items	0.302	47.889	28.244	26.696	14.437
Cash Taxes Paid	34.365	16.515	10.279	6.505	4.046
Changes in Working Capital	-63.811	-102.128	-48.62	-1.135	-14.133
Cash From Investing Activities	-233.236	-221.169	-201.385	-205.308	-14.037
Capital Expenditures	-88.346	-71.276	-26.344	-23.154	-12.782
Other Investing Cash Flow Items, Total	-144.89	-149.893	-175.041	-182.154	-1.255
Cash From Financing Activities	-13.337	0.961	305.916	484.867	3.407
Financing Cash Flow Items	-17.018	-2.897	-0.01	-0.49	0
Issuance (Retirement) of Stock, Net	3.707	3.879	305.926	321.88	3.418
Issuance (Retirement) of Debt, Net	-0.026	-0.021	0	163.477	-0.011
Foreign Exchange Effects	-5.866	-12.286	12.729	-3.19	-2.077
Net Change in Cash	-80.356	-113.478	179.885	343.585	20.063
Cash Interest Paid	1.033	1.066	1.066	1.484	2.444

	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022
Net income/Starting Line	28.829	185.959	137.23	96.825	46.964
Cash From Operating Activities	11.154	172.083	110.201	68.834	23.113
Cash From Operating Activities	15.252	50.985	36.605	23.933	11.834
Deferred Taxes	-1.124	-1.352	1.722	0.738	1.045
Non-Cash Items	8.089	0.302	11.02	6.786	6.029
Changes in Working Capital	-39.892	-63.811	-76.376	-59.448	-42.759
Cash From Investing Activities	-9.433	-233.236	-111.928	-54.434	-28.214
Capital Expenditures	-9.433	-88.346	-66.958	-54.451	-28.231
Other Investing Cash Flow Items, Total	0	-144.89	-44.97	0.017	0.017
Cash From Financing Activities	-9.563	-13.337	-13.063	-14.314	-12.021
Financing Cash Flow Items	-9.592	-17.018	-15.829	-14.759	-12.311
Issuance (Retirement) of Stock, Net	0.029	3.707	2.784	0.463	0.296
Issuance (Retirement) of Debt, Net	0	-0.026	-0.018	-0.018	-0.006
Foreign Exchange Effects	0.993	-5.866	-15.661	-7.388	-2.052
Net Change in Cash	-6.849	-80.356	-30.451	-7.302	-19.174
Cash Taxes Paid
Cash Interest Paid

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

1:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Repligen Company profile

About Repligen Corporation

Repligen Corporation is a life sciences company that develops and commercializes bioprocessing technologies and systems that rises flexibility in the process of manufacturing biological drugs. The Company's bioprocessing business consist of four franchises, Filtration; Chromatography; Process Analytics; and Proteins. The Filtration products are used in process development and process scale (clinical and commercial) production. The Chromatography franchise includes products used in downstream purification, development, and manufacturing of biological drugs. The Process Analytics products allow end-users to make in-line absorbance measurements allowing for the determination of protein concentration in filtration, chromatography formulation and fill-finish applications. The Proteins franchise is represented by its Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification of virtually all mAb-based drugs on the market.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Repligen Corporation revenues increased 83% to $670.5M. Net income increased from $59.9M to $128.3M. Revenues reflect Product revenue - Filtration products segment increase from $174.9M to $403.5M, Product revenue - Protein products segment increase of 53% to $123.7M, Europe segment increase of 83% to $254.8M, North America segment increase of 56% to $274.9M.

Equity composition

Common Stock $.01 Par, 01/11, 40M auth., 30,787,307 issd. Insiders & strategic holders own 13.21%. PO 5/91, 2M shares @ $12.50 by Lehman Bros. Public Offering 2/94, 2.9M shares @ $6 by Lehman Brothers.

Industry:

Medical Equipment, Supplies & Distribution (NEC)

Building 1, Suite 100
41 Seyon Street
WALTHAM
MASSACHUSETTS 02453
US

Income Statement

Annual
Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024